| Nanoparticle Mediated Targeted Drug Delivery in Autoimmune Diseases: Advances in Clinical Pharmacology |
| Paper ID : 1299-IGA |
| Authors |
|
Mehrasa Nikandish * King’s College London; BPharm, University of Georgia, Georgia |
| Abstract |
| Autoimmune diseases pose a major clinical challenge due to the need for immunomodulation without broadly suppressing host defense, as well as the chronic nature of many conditions. Classical therapies (e.g. corticosteroids, biologics, small molecule immunosuppressants) often suffer from systemic toxicity, off target effects, and variable pharmacokinetics. Nanoparticle (NP) mediated drug delivery offers opportunities to enhance tissue targeting, improve pharmacodynamics, modulate immune responses more precisely, and reduce adverse effects. This article reviews recent advances in nanoparticle design and application in autoimmune disease models (e.g., rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel diseases, myasthenia gravis), with a focus on mechanisms, pharmacokinetics/pharmacodynamics (PK/PD), clinical translation prospects, remaining challenges, and potential future directions. y, and reduce adverse effects. This article reviews recent advances in nanoparticle design and application in autoimmune disease models (e.g., rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel diseases, myasthenia gravis), with a focus on mechanisms, pharmacokinetics/pharmacodynamics (PK/PD), clinical translation prospects, remaining challenges, and potential future directions. |
| Keywords |
| Nanomedicine; Autoimmune Diseases; Targeted Drug Delivery; Nanoparticles; Clinical Pharmacology; Immunomodulation; Rheumatoid Arthritis; Systemic Lupus Erythematosus; Inflammatory Bowel Disease; Myasthenia Gravis; |
| Status: Accepted |
